REBLOZYL (luspatercept-aamt) for injection, for subcutaneous use. Initial U.S. Approval: 2019

REBLOZYL (luspatercept-aamt) for injection, for subcutaneous use. Initial U.S. Approval: 2019

INDICATIONS AND USAGE
REBLOZYL is an erythroid maturation agent indicated for the treatment of anemia in:
• Adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions.
DOSAGE FORMS & STRENGTHS
• For injection: 25 mg lyophilized powder in a single-dose vial for reconstitution.
• For injection: 75 mg
Manufactured By: Celgene Corporation
Prescribing Information URL: Click Here

Access to REBLOZYL ® (luspatercept-aamt) for injection: Anticancer drugs available upon request. To get best price please share your mobile number to receive quotes from Medvitaz Pharma Solutions.

Luspatercept, sold under the brand name Reblozyl, is a medication used for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. It was developed by Acceleron Pharma in collaboration with Celgene.

The U.S. Food and Drug Administration (FDA) awarded orphan drug status in 2013, and fast track designation in 2015, for both indications. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.

Reviews

There are no reviews yet.

Add a review

neeraj
Neeraj Nagpal

Head of Operations

 The profound knowledge of more than 20 years in sales and marketing sector, he has been working dedicatedly and contributing to pharmaceuticals industry. He handles all operations over the country.

Contact Our Team

Contact us and we will reply as soon as possible!

    need help?

     MEDVITAZ is an initiative for helping end-users directly to get the right medicines and right medical treatments from the right source.